Buy Mexidol solution intravenously and intramuscularly 50 mg/ml 2 ml No. 10 in pharmacies

Nosological classification (ICD-10)

• E63 Physical and mental overload
• F06.7 Mild cognitive impairment
• F07.2 Post-concussion syndrome
• F10.3 Withdrawal state
• F41.9 Anxiety disorder, unspecified
• F45 Somatoform disorders
• F48.9 Neurotic disorder, unspecified
• G45 Transient transient cerebral ischemic attacks [attacks] and related syndromes
• G90 Disorders of the autonomic nervous system
• G92 Toxic encephalopathy
• G93.4 Encephalopathy, unspecified
• I25.9 Chronic ischemic heart disease, unspecified
• I67.4 Hypertensive encephalopathy
• I67.9 Cerebrovascular disease, unspecified
• R41.8.0* Intellectual-mnestic disorders
• R45.7 State of emotional shock and stress, unspecified
• R53 Malaise and fatigue
• S06 Intracranial injury
• T43.3 Poisoning with antipsychotic and antipsychotic drugs
• T90.5 Consequences of intracranial injury

Side effects

Despite the fact that the body, as a rule, takes the drug positively, and the drug itself has a low level of toxicity, it still has side effects that are prescribed in Mexidol's instructions for use; you can read reviews on the Internet.

• If we consider the cardiovascular system, then this includes: a significant increase or decrease in blood pressure.
• Nervous system: fatigue, anxiety, excessive emotionality, pain, dysfunction of the vestibular apparatus.
• Gastrointestinal tract: vomiting, dehydration, which contributes to severe thirst.
• The body's immune system: the appearance of allergic reactions (rashes on the skin, scabies).
• Other criteria: distal hyperhidrosis.

Mexidol in ampoules

Compound

Pharmacodynamics

Mexidol® is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body's resistance to the effects of various damaging factors (shock, hypoxia and ischemia, cerebrovascular accidents, intoxication with alcohol and antipsychotics (neuroleptics).

The mechanism of action of Mexidol® is due to its antioxidant, antihypoxic and membrane protective effects. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces membrane viscosity, and increases its fluidity.

Mexidol® modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improve synaptic transmission.

Mexidol® increases the content of dopamine in the brain. Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes. The drug improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a lipid-lowering effect, reduces the content of total cholesterol and LDL.

The anti-stress effect is manifested in the normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wake cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various structures of the brain.

Mexidol® has a pronounced antitoxic effect in withdrawal symptoms. It eliminates the neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, autonomic functions, and is also able to relieve cognitive impairment caused by long-term use of ethanol and its withdrawal.

Under the influence of Mexidol®, the effect of tranquilizing, neuroleptic, antidepressant, hypnotics and anticonvulsants is enhanced, which makes it possible to reduce their doses and reduce side effects.

Mexidol® improves the functional state of ischemic myocardium. In conditions of coronary insufficiency, it increases collateral blood supply to the ischemic myocardium, helps maintain the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.

Analogs

The pharmaceutical market sells not only Mexidol, but also its analogues (see Mexidol instructions for use analogues ). The products differ in their composition, that is, the main substance, additional ingredients, manufacturers, and the quality of purification of the materials used. For this reason, after receiving consultation recommendations from pharmacies, you can choose medications for yourself that are similar in their characteristics and purpose to Mexidol tablets.

Similar analogues include:

• Medomexy;
• Mexiprim;
• Mexidant;
• Mexipridol;
• Mexicofin;
• Neurox;
• Cerecard.

In accordance with the therapeutic effect, the following agents are considered identical to the suspension solution:

• Medomexy;
• Armadin;
• Mexico;
• Astrox;
• Mexipridol;
• Mexiprim.

Naturally, the required effect can be achieved with the help of other substances, however, it is worth remembering that not in all cases analogues may be perfect as an alternative to a drug prescribed by a doctor, so replacements should be made only after the recommendations of a qualified doctor.

Pharmacokinetics

Rapidly absorbed when taken orally. When taken orally in doses of 400–500 mg, Cmax is 3.5–4 mcg/ml. Quickly distributed in organs and tissues. The average retention time of the drug in the body when taken orally is 4.9–5.2 hours.

Metabolized in the liver by glucuron conjugation. 5 metabolites have been identified: 3-hydroxypyridine phosphate - formed in the liver and, with the participation of alkaline phosphate, breaks down into phosphoric acid and 3-hydroxypyridine; 2nd metabolite - pharmacologically active, formed in large quantities and found in urine 1–2 days after administration; 3rd - excreted in large quantities in the urine; 4th and 5th - glucuron conjugates.

T1/2 when taken orally - 2–2.6 hours. It is quickly excreted in the urine, mainly in the form of metabolites and in small quantities unchanged. The most intensive elimination occurs during the first 4 hours after taking the drug. Rates of urinary excretion of unchanged drug and metabolites have individual variability.

Indications for the drug Mexidol®

consequences of acute cerebrovascular accidents, incl. after transient ischemic attacks, in the subcompensation phase as preventive courses;

mild traumatic brain injury, consequences of traumatic brain injury;

encephalopathies of various origins (dyscirculatory, dysmetabolic, post-traumatic, mixed);

autonomic dystonia syndrome;

mild cognitive disorders of atherosclerotic origin;

anxiety disorders in neurotic and neurosis-like conditions;

coronary heart disease (as part of complex therapy);

relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-withdrawal disorders;

conditions after acute intoxication with antipsychotic drugs;

asthenic conditions;

prevention of the development of somatic diseases under the influence of extreme factors and stress;

exposure to extreme (stress) factors.

Interaction with other medications

Mexidol has demonstrated itself as a medicine that has a high degree of compatibility with other drugs, including those used for the treatment of pathological phenomena in the field of neurology.

However, it is worth immediately noting that Mexidol can enhance the effect of drugs such as benzodiazepines, carbamazepine and drugs for the treatment of Parkinson's disease, hypnotics and anti-seizure drugs. This makes it possible to reduce their dosage and eliminate most signs of the clinical picture.

Mexidol reduces the toxicity and harmfulness of ethyl alcohol. This is a rather useful feature that is used when carrying out therapeutic measures against the physical and mental disorders of alcohol syndrome.

Directions for use and doses

Orally, 125–250 mg 3 times a day; the maximum daily dose is 800 mg (6 tablets).

Duration of treatment - 2–6 weeks; to relieve alcohol withdrawal – 5–7 days. Treatment is stopped gradually, reducing the dose over 2-3 days.

The initial dose is 125–250 mg (1–2 tablets) 1–2 times a day with a gradual increase until a therapeutic effect is obtained; the maximum daily dose is 800 mg (6 tablets).

The duration of therapy in patients with coronary artery disease is at least 1.5–2 months. Repeated courses (on the recommendation of a doctor) are preferably carried out in the spring and autumn.

Mexidol dosage

IM or IV (stream or drip). When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution.

Mexidol® is administered slowly over 5–7 minutes in a stream, and dropwise at a rate of 40–60 drops per minute. The maximum daily dose should not exceed 1200 mg.

For acute cerebrovascular accidents, Mexidol® is used in the first 10–14 days - 200–500 mg IV drip 2–4 times a day, then 200–250 mg IM 2–3 times a day for 2 weeks .

For traumatic brain injury and the consequences of traumatic brain injuries, Mexidol® is used for 10-15 days intravenously at a dose of 200–500 mg 2–4 times a day.

For dyscirculatory encephalopathy in the decompensation phase, Mexidol® should be prescribed intravenously in a stream or drip at a dose of 200–500 mg 1–2 times a day for 14 days. Then IM 100–250 mg/day over the next 2 weeks.

For a course of prophylaxis of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 200–250 mg 2 times a day for 10–14 days.

For mild cognitive impairment in elderly patients and anxiety disorders, the drug is used intramuscularly at a daily dose of 100–300 mg/day for 14–30 days.

In case of acute myocardial infarction, as part of complex therapy, Mexidol® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic means according to indications.

In the first 5 days, to achieve maximum effect, it is advisable to administer the drug intravenously; in the next 9 days, Mexidol® can be administered intramuscularly.

Intravenous administration of the drug is carried out by drip infusion, slowly (to avoid side effects) in a 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100–150 ml for 30–90 minutes. If necessary, a slow jet injection of the drug, lasting at least 5 minutes, is possible.

The drug is administered (intravenous or intramuscular) 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg/kg body weight per day, a single dose is 2-3 mg/kg body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.

For open-angle glaucoma of various stages, as part of complex therapy, Mexidol® is administered intramuscularly at 100–300 mg/day, 1–3 times a day for 14 days.

For alcohol withdrawal syndrome, Mexidol® is administered in a dose of 200–500 mg intravenously or intramuscularly 2–3 times a day for 5–7 days.

In case of acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 200-500 mg/day for 7-14 days. In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis), the drug is prescribed on the first day both in the preoperative and postoperative periods. The administered doses depend on the form and severity of the disease, the prevalence of the process, and variants of the clinical course. The drug should be discontinued gradually only after a stable positive clinical and laboratory effect.

For acute edematous (interstitial) pancreatitis, Mexidol® is prescribed 200–500 mg 3 times a day, intravenously (in 0.9% sodium chloride solution) and intramuscularly. Mild severity of necrotizing pancreatitis - 100-200 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly. Moderate severity - 200 mg 3 times a day intravenously (in 0.9% sodium chloride solution). Severe course - in a pulse dosage of 800 mg on the first day with a double dose regimen; then 200–500 mg 2 times a day with a gradual reduction in the daily dose. Extremely severe course - at an initial dosage of 800 mg/day until the manifestations of pancreatogenic shock are persistently relieved, after stabilization of the condition, 300-500 mg 2 times a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.